Publication Name	World Journal of Hepatology
Manuscript ID	41170
Country	Greece

Received	2018-07-31 02:34
Peer-Review Started	2018-07-31 09:14
To Make the First Decision	2018-08-21 01:48
Return for Revision	2018-08-22 01:10
Revised	2018-09-10 20:14
Second Decision	2018-09-12 10:29
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-10-10 05:46
Articles in Press	2018-10-10 05:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-11-21 08:39
Publish the Manuscript Online	2018-11-27 13:56

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
Manuscript Source	Invited Manuscript
All Author List	Maria Kalogirou and Emmanouil Sinakos
ORCID	Author(s) ORCID Number Maria Kalogirou http://orcid.org/orcid.org/0000-0001-9985-4038 Emmanouil Sinakos http://orcid.org/0000-0003-0923-050X
Funding Agency and Grant Number
Corresponding Author	Emmanouil Sinakos, MD, PhD, Assistant Professor, 4th Department of Internal Medicine, Hippocrates Hospital, Aristotle University of Thessaloniki, 49, Konstantinopoleos Street, Thessaloniki 54642, Greece. em_sinakos@yahoo.com
Key Words	Nonalcoholic steatohepatitis; Cirrhosis; Glucagon-like peptide-1 receptor agonists; Nonalcoholic fatty liver disease
Core Tip	There is an urgent need for an effective treatment of nonalcoholic fatty liver disease (NAFLD). Growing evidence indicates that reducing insulin resis­tance can result in improvement of the biochemical and histological features of patients with nonalcoholic steatohepatitis (NASH). However, no antidiabetic agent to date has been proven as both safe and effe­ctive for the treatment of patients with NASH. Re­cent studies have demonstrated that glucagon-like peptide-1 agonists, a novel class of antidiabetic drugs, may be effective in slowing the progression of NAFLD, highlighting their potential role in the treatment of this complex disease.
Publish Date	2018-11-27 13:56
Citation	Kalogirou M, Sinakos E. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World J Hepatol 2018; 10(11): 790-794
URL	http://www.wjgnet.com/1948-5182/full/v10/i11/790.htm
DOI	http://dx.doi.org/10.4254/wjh.v10.i11.790

Full Article (PDF)	WJH-10-790.pdf
Full Article (Word)	WJH-10-790.doc
Manuscript File	41170-Review.docx
Answering Reviewers	41170-Answering reviewers.pdf
Audio Core Tip	41170-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	41170-Conflict-of-interest statement.pdf
Copyright License Agreement	41170-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	41170-Language certificate.pdf
Peer-review Report	41170-Peer-review(s).pdf
Scientific Misconduct Check	41170-Scientific misconduct check.pdf
Scientific Editor Work List	41170-Scientific editor work list.pdf